Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics.

ABSTRACT: Diabetes mellitus is a major health problem with increasing prevalence at a global level. The discovery of insulin in the early 1900s represented a major breakthrough in diabetes management, with further milestones being subsequently achieved with the identification of glucagon-like peptide-1 (GLP-1) and the introduction of GLP-1 receptor agonists (GLP-1 RAs) in clinical practice. Moreover, the subcutaneous delivery of biotherapeutics is a well-established route of administration generally preferred over the intravenous route due to better patient compliance and prolonged drug absorption. However, current subcutaneous formulations of GLP-1 RAs present pharmacokinetic problems that lead to adverse reactions and treatment discontinuation. In this review, we discuss the current challenges of

SUBMITTER: Bendicho-Lavilla C 

PROVIDER: S-EPMC8897023 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature